X0306 4 2021-07-01 0 0001000694 NOVAVAX INC NVAX 0001342826 Erck Stanley C C/O NOVAVAX, INC. 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 1 1 0 0 President and CEO Common Stock 2021-07-01 4 M 0 15181 25.60 A 35676 D Common Stock 2021-07-01 4 M 0 19879 36.60 A 55555 D Common Stock 2021-07-01 4 M 0 17560 121.00 A 73115 D Common Stock 2021-07-01 4 S 0 2046 209.2027 D 71069 D Common Stock 2021-07-01 4 S 0 6105 210.0229 D 64964 D Common Stock 2021-07-01 4 S 0 4117 211.0679 D 60847 D Common Stock 2021-07-01 4 S 0 6419 212.1527 D 54428 D Common Stock 2021-07-01 4 S 0 12703 213.071 D 41725 D Common Stock 2021-07-01 4 S 0 12917 214.127 D 28808 D Common Stock 2021-07-01 4 S 0 6984 214.9681 D 21824 D Common Stock 2021-07-01 4 S 0 1329 215.6983 D 20495 D Common Stock 2021-07-02 4 M 0 25120 36.60 A 45615 D Common Stock 2021-07-02 4 M 0 27439 121.00 A 73054 D Common Stock 2021-07-02 4 S 0 1970 210.2299 D 71084 D Common Stock 2021-07-02 4 S 0 4242 211.2084 D 66842 D Common Stock 2021-07-02 4 S 0 7616 212.2878 D 59226 D Common Stock 2021-07-02 4 S 0 2355 213.3849 D 56871 D Common Stock 2021-07-02 4 S 0 4466 214.7581 D 52405 D Common Stock 2021-07-02 4 S 0 5190 215.7406 D 47215 D Common Stock 2021-07-02 4 S 0 2994 216.9188 D 44221 D Common Stock 2021-07-02 4 S 0 9969 217.8405 D 34252 D Common Stock 2021-07-02 4 S 0 7423 218.7717 D 26829 D Common Stock 2021-07-02 4 S 0 5031 219.7605 D 21798 D Common Stock 2021-07-02 4 S 0 628 220.8006 D 21170 D Common Stock 2021-07-02 4 S 0 675 221.5281 D 20495 D Stock Option (Right to Buy) 25.60 2021-07-01 4 M 0 15181 0.00 D 2022-03-01 Common Stock 15181 0 D Stock Option (Right to Buy) 36.60 2021-07-01 4 M 0 19879 0.00 D 2023-03-02 Common Stock 19879 25120 D Stock Option (Right to Buy) 121.00 2021-07-01 4 M 0 17560 0.00 D 2024-03-06 Common Stock 17560 27439 D Stock Option (Right to Buy) 36.60 2021-07-02 4 M 0 25120 0.00 D 2023-03-02 Common Stock 25120 0 D Stock Option (Right to Buy) 121.00 2021-07-02 4 M 0 27439 0.00 D 2024-03-06 Common Stock 27439 0 D The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.56 to $209.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.57 to $210.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.57 to $211.47, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.58 to $212.57, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.60 to $213.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.61 to $214.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.63 to $215.55, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.63 to $215.84, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.75 to $210.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.82 to $211.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.82 to $212.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.87 to $213.84, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.20 to $215.16, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.24 to $216.17, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.26 to $217.18, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.28 to $218.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.33 to $219.30, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.33 to $220.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.34 to $221.20, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.38 to $222.33, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date. The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date. The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 6, 2014 grant date. /s/ John A. Herrmann III, Attorney-in-Fact 2021-07-06